After a turbulent year for the clinical research sector, hVIVO plc (AIM: HVO) has found itself back in penny-stock territory. Its share price, which stood at 29.8 GBX in November
hVIVO plc (AIM: HVO) Positive data from novel human challenge models
Positive data from multiple novel human challenge models hVIVO presentations made at influential ESWI and World Vaccine Congress Europe conferences
hVIVO plc (AIM: HVO) Presentation at Jefferies Healthcare Conference
hVIVO to present at Jefferies Global Healthcare Conference
Genflow Biosciences Shares Jump 25% on Positive Dog Aging Gene Therapy Results
Update on Animal Health Program
Genflow Biosciences (LON: GENF) Shares Jump 100% After Alternative Share Placement
Genflow Biosciences Raises £440,000 Through Alternative Share Placement.
hVIVO plc – Unaudited Interim Results for Six Months Ended 30 June 2025
Interim results Trading in line with expectations for full year Returning to growth in 2026
Genflow Biosciences (LON: GENF) Files Patent Examination Request in China for SIRT6 Variants in NASH
Genflow Biosciences PLC (LON: GENF) has submitted a formal request for examination of its patent application in China relating to proprietary SIRT6 variants designed for the treatment of Non-Alcoholic Steatohepatitis
hVIVO plc (AIM: HVO) Appointment of Non-Executive Chair
hVIVO plc (AIM: HVO), a full-service Contract Research Organisation (CRO) and the world leader in human challenge clinical trials, confirms that, further to its announcement on 29 July 2025, Shaun
hVIVO plc (AIM: HVO) Proposed appointment of Chair
hVIVO plc (AIM: HVO), a full-service Contract Research Organisation and the world leader in human challenge clinical trials, announces the appointment of Shaun Chilton as Non-Executive Chair, subject to successful completion of
Genflow Biosciences Advances Toward Human Trials for Ageing Therapies
Genflow Biosciences PLC (LSE: GENF, OTCQB: GENFF) has announced progress across its two core research programmes, bringing it closer to initiating human trials for its gene therapies targeting age-related diseases.
hVIVO PLC (AIM:HVO) Notice of Trading Update
hVIVO plc (AIM: HVO), a full-service Contract Research Organisation (CRO) and the world leader in human challenge clinical trials, confirms that it will issue a trading update for the six months ended 30
hVIVO PLC (AIM:HVO) Positive results from client Phase 2b field study
Positive topline results from client Phase 2b field study